Target-selective peptide-cleaving catalysts as a new paradigm in drug design.
This tutorial review describes the evolution of peptide-hydrolyzing metal catalysts towards artificial metalloproteases cleaving target proteins selectively. The catalytic cleavage of the backbone of a protein related to a disease may effect a cure. In particular, a new therapeutic option for amyloid diseases such as Alzheimer's disease, diabetes and Parkinson's disease has been presented. The new paradigm of drug design based on artificial metalloproteases should be of interest to researchers in the areas of biomimetic chemistry, as well as medicinal chemistry.
Lee
Tae Yeon
TY
Department of Chemistry, Seoul National University, Seoul 151-747, Korea.
Suh
Junghun
J
D000682:Amyloid / Q000737:chemistry / Q000378:metabolism*; D000818:Animals; D032701:Biomimetics / Q000379:methods*; D002384:Catalysis; D015195:Drug Design; D006801:Humans; D045726:Metalloproteases / Q000737:chemistry / Q000378:metabolism; D008670:Metals / Q000737:chemistry / Q000378:metabolism*; D008958:Models, Molecular; D010455:Peptides / Q000737:chemistry / Q000378:metabolism*
D000682:Amyloid; D008670:Metals; D010455:Peptides; D045726:Metalloproteases